Medindia LOGIN REGISTER
Medindia

Pediatric Eye Cancer Could be Treated With Virus-Based Therapy

by Mohamed Fathima S on Jan 24 2019 12:38 PM

Cancer-killing, virus-based therapy showed promising effects against retinoblastoma, eye cancer occurring in children, in mouse models and a pilot clinical trial.

Pediatric Eye Cancer Could be Treated With Virus-Based Therapy
Retinoblastoma, an eye cancer affecting the retina, most predominantly occurs in the children. A cancer-killing, virus-based therapy showed promising effects against cancer in a pilot clinical trial and mouse models.
Although further work //is needed, the therapy lays the groundwork for new treatment options for the cancer, which is currently treated with disfiguring surgery.

Researchers estimate that retinoblastoma causes 8,000 cases each year, a figure that represents 11% of all cancers in children under the age of one. Most cases result from inactivation of the gene RB1, which normally plays a critical role as a tumor suppressor. Chemotherapy is the standard-of-care for retinoblastoma, but intensive rounds of such drugs can damage the retina and cause long-term vision problems. In some cases, surgery is needed to remove the eye entirely - an invasive procedure called enucleation that results in loss of vision.

Here, Guillem Pascual-Pasto and colleagues investigated an alternative treatment for retinoblastoma named VCN-01, which harnesses a virus that infects and kills cancer cells harboring a dysfunctional RB1 pathway. The treatment was safe in juvenile rabbit models, and injections of the virus into the eyes of mice with retinoblastoma (equivalent to a feasible dosage for human children) curtailed tumor growth, prevented metastasis, and extended the time to enucleation compared to chemotherapy.

Importantly, the authors administered VCN-01 to two pediatric patients with retinoblastoma and observed the virus successfully replicated in tumor cells and did not cause systemic inflammation. Taken together, the findings warrant further development of VCN-01 as a potential treatment for patients with retinoblastoma and RB1 inactivation, Pascual-Pasto et al. say.



Source-Eurekalert


Advertisement